美国《新英格兰医学杂志》（NEJM）网络版11月4日发表一份最新研究报告说，一种名为Prasugrel的新药具有比某种主流药物更好的抗凝血效果，可用于心脏病等相关疾病的治疗。但该药同时会增加严重出血的风险。

    研究报告说，许多心脏病患者需要使用抗凝血药物来稀释血液和减少血栓，Prasugrel在这方面比目前的主流药物Plavix更有效果。与后者相比，服用新药的病人心脏病发作、中风、因心脏病死亡的综合风险要低20%，并且见效更快，服药3天后就有较好的效果。

    另一方面，新药增加了严重出血的风险，这意味着它对于老人等人群来说更有风险。但美国克利夫兰诊所的心脏病专家迪帕克·巴特评论说，这是为取得更好的抗凝血效果“需付的代价”。

    这种新药是美国礼来公司和一家日本公司联合开发的。（新华网）

原始出处:

Published at www.nejm.org November 4, 2007 (10.1056/NEJMoa0706482)

 Background Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention.

Methods To compare prasugrel, a new thienopyridine, with clopidogrel, we randomly assigned 13,608 patients with moderate-to-high-risk acute coronary syndromes with scheduled percutaneous coronary intervention to receive prasugrel (a 60-mg loading dose and a 10-mg daily maintenance dose) or clopidogrel (a 300-mg loading dose and a 75-mg daily maintenance dose), for 6 to 15 months. The primary efficacy end point was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The key safety end point was major bleeding.

Results The primary efficacy end point occurred in 12.1% of patients receiving clopidogrel and 9.9% of patients receiving prasugrel (hazard ratio for prasugrel vs. clopidogrel, 0.81; 95% confidence interval [CI], 0.73 to 0.90; P<0.001). We also found significant reductions in the prasugrel group in the rates of myocardial infarction (9.7% for clopidogrel vs. 7.4% for prasugrel; P<0.001), urgent target-vessel revascularization (3.7% vs. 2.5%; P<0.001), and stent thrombosis (2.4% vs. 1.1%; P<0.001). Major bleeding was observed in 2.4% of patients receiving prasugrel and in 1.8% of patients receiving clopidogrel (hazard ratio, 1.32; 95% CI, 1.03 to 1.68; P=0.03). Also greater in the prasugrel group was the rate of life-threatening bleeding (1.4% vs. 0.9%; P=0.01), including nonfatal bleeding (1.1% vs. 0.9%; hazard ratio, 1.25; P=0.23) and fatal bleeding (0.4% vs. 0.1%; P=0.002).

相关报道:

抗凝血药

生物技术公司Regado开发抗凝血药

FDA拒绝批准阿斯利康抗凝血药Exanta

全球首次人工合成抗凝血药物

影响药物效应的因素及合理用药原则

中美科学家研发成功全球首例人工合成肝素

凝血及溶血检验

抗血小板药

专利过期药的仿制 制药业面临三大新机遇